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Medicare Coverage and
Technology Diffusion
In 1989 the National Health Policy Forum held a
session entitled “Medicare Coverage: Translating Process
into Practice.” Now, nine years later, it is holding another
meeting looking at the same proposed rule, issued in 1989
by the Health Care Financing Administration (HCFA), on
Medicare coverage of services and products and exploring a process that has changed little over the past decade.
The issues remain fundamentally the same. Only now the
issue of coverage—for Medicare as well as for private
plans—has become more complex as the market has
fractured into a range of health plans. As Medicare dips
its toes into the managed care waters through its Medicare
+ Choice program, it will have to resolve the dilemma all
plans are facing: balancing risk with coverage policy.
Under managed care, as more risk is shifted to providers,
the coverage issue changes its character. Providers no
longer have the clear incentives to adopt new technology
they once had under fee-for-service reimbursement.
Today, those incentives are more diluted.
Criticisms of the Medicare coverage process include
lack of openness, lack of public participation, lack of
predictability, lack of precise definitions of key terms
and criteria, and lack of an adequate appeals process. In
part, these criticisms are a manifestation of the tension
Medicare faces in balancing the encouragement of
innovation and quality of care against the proliferation
of inappropriate services and the escalation of health
care costs. The challenge lies in providing Medicare
beneficiaries with access to the newest medical technologies whose costs are justified by improvements in
health outcomes while limiting access to technologies
of lesser or unknown value.
Medicare coverage is critical for successful technology diffusion. Complicating this process, however, is
the nonlinear, incremental nature of innovation in
medical technology. For example, before a device is
deemed effective enough for coverage, it may need to
be used by patients and physicians and improved over
a period of time as it diffuses into everyday medical
practice. On the other hand, successful diffusion may
depend on whether or not the device is covered. Thus,
coverage determination and technology innovation can
become ensnared in a classic catch-22.
Coverage determination does not occur in a vacuum.
It is part of a continuum that includes technology assessment, payment determination (for example, method, site,

and level of payment), and the demand for evidence (for
example, quality of life data, economic outcomes, and
societal costs). Medicare coverage, which involves
different levels of decision making, highlights the
important role the physician plays in determining
medical necessity. This Forum session will look at the
Medicare coverage process, examine its strengths and
weaknesses, and review options for its improvement.

THE PAST: LEGISLATING AND
REGULATING MEDICARE COVERAGE
Congress established the Medicare program in 1965
with the enactment of title XVIII of the Social Security
Act. While the law provides for the coverage of broad
categories of benefits, such as inpatient hospital care, it
does not include a specific list of services actually covered. It was inevitable that, over time, particularly with the
development of new technologies, questions would arise
requiring individual coverage determinations. Congress
anticipated this need and provided the secretary of health
and human services with the authority to make these
decisions. Section 1862 (a)(1)(A) of the Act states:
Notwithstanding any other provisions of this title, no
payment may be made under Part A or Part B for any
expenses incurred for items or services which are not
reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning
of a malformed body member.
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The regulations implementing the “reasonable and
necessary” section of the law are quite general [42 CFR
405.310 (k)]. Although the criteria that a health care
technology must meet in order to be considered reasonable and necessary are specified, precise definitions do
not exist. Historically, reasonable and necessary has
been largely defined by the local physician community.
Determinations about whether services are reasonable
and necessary and, therefore, covered under Medicare
have wide-felt repercussions. They have, for example,
considerable impact on the shape of the health care
marketplace. A negative coverage decision may slow
down or even halt the diffusion of a new technology, in
turn limiting the services physicians may feel free to use.
From the patient’s point of view, he or she may be denied
needed services for which technology does exist but
coverage—and therefore payment—does not.
On April 29, 1987, HCFA published a notice (52 FR
15560) in the Federal Register announcing its process
for making coverage decisions. This notice was the
result of Jameson v. Bowen, a lawsuit in which the
plaintiff sued to have HCFA reimburse him for a
percutaneous transluminal coronary angioplasty
(PTCA) procedure performed before a coverage determination had been made. In addition to reimbursing the
plaintiff, HCFA agreed to publish the notice. On
January 30, 1989, HCFA published another proposed
rule expanding upon this 1987 description of the
process. The 1989 proposed rule moved to clarify some
of the uncertainty, explaining that
Although the process by which we make Medicare
coverage decisions on health care technology has been
in place for many years, we believe there are segments
of the population that may still benefit from a complete description of the coverage decision making
process. We also believe the process should be more
open and that the review of breakthrough technologies
should be streamlined. It is for these reasons that we
are now presenting the coverage decisions process as
a public document.

Many experts, however, argued that HCFA’s proposed
rule did not go far enough. Further, some of its elements, such as the cost-effectiveness component, were
highly controversial. A modest effort to issue the 1989
regulation in final form died in 1996, highlighting again
the controversial nature of coverage decision making.

THE PRESENT: THE MEDICARE
COVERAGE PROCESS EXPLAINED1
Coverage involves deciding whether or not to pay
for a particular service or product, while reimbursement

involves determining the methods and amounts of
payment for covered services and products. To be paid
by the Medicare program, all services and products
must be covered by HCFA, the agency that administers
the program. That is, the services or procedures and the
products used in them must be deemed to be reasonable
and necessary for diagnosing or treating a patient. They
must also fit into particular statutory categories, such as
hospital services, surgical dressings, durable medical
equipment, prosthetics and orthotics, or supplies
incident to a physician’s services.
The vast majority of Medicare coverage decisions
are made by its contractors, known as fiscal intermediaries for Medicare Part A (inpatient) services and
carriers for Medicare Part B (outpatient, physician,
clinical laboratory, and medical supplier) services.
These contractors are private insurance companies that
contract with Medicare to process claims from beneficiaries, providers, and suppliers.
Medicare coverage is carried out at three levels:
local, regional, and national. Figure 1 (see page 9)
depicts the local and national coverage decision-making
process for Medicare.

Local Coverage
In deciding whether to cover a medical service or
technology, contractors review applicable manuals for
specific product- or procedure-related policies supplied by HCFA or apply general criteria such as the
following: Is the product safe and effective? Is it
reasonable and necessary? Is it appropriate? Is it
experimental or investigational?
Many carriers maintain medical advisory committees
comprising local specialists to advise them on new
procedures and technologies. These advisory committees, along with medical directors and medical policy
staff of the carriers, play an important role in reviewing
new technologies and making local coverage decisions.
Such decisions are often printed in local carrier bulletins or newsletters.
Local coverage decision making has been viewed as
a double-edged sword by many. On the one hand,
decisions are not standardized, since each contractor
makes separate decisions. What is covered in one
locality may not be in another. From a manufacturer,
physician, and patient point of view, this process, while
sometimes confusing and frustrating, allows for coverage in some circumstances as the new technology
diffuses. A national decision, on the other hand, while
uniform and standard, can be a death sentence for a
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technology if a national noncoverage determination is
handed down by HCFA’s central office.

product has been cleared by the Food and Drug Administration (FDA).

Regional Coverage

In early 1994, the Department of Health and Human
Services, Office of Inspector General sent subpoenas to
more than 135 hospitals asking for information about
products billed to Medicare and Medicaid that had been
used in services covered by the program but had not been
approved for those purposes by the FDA. By the second
half of 1994, HCFA was rigorously enforcing the practice
of not paying for services in which medical devices that
had not received an FDA premarket approval were used.
(This practice is not required by the Medicare statute and
is not contained in the HCFA regulatory manual.) The
development raised significant questions about the precise
role of FDA approval in Medicare coverage determinations, as well as about the use of a product outside the
scope of its labeled indications.

In 1993 and 1994, Medicare Part B claims processing for certain products was transferred from 34 local
carriers to four regional carriers, known as durable
medical equipment carriers (DMERCs). These carriers
process claims for durable medical equipment, prosthetics, orthotics, surgical dressings, and a wide array of
supplies used in the patient’s home. Each DMERC has
issued a manual with detailed coverage and payment
policies on particular product areas, such as infusion
pumps, wheelchairs, and orthopedic support devices.

National Coverage
Under certain circumstances, HCFA may decide that
a technology requires a national coverage decision
—that is, one that applies to all contractors. Such a
decision may be warranted, for example, if a device is
likely to result in a major increase in Medicare costs or
provide important therapeutic benefits.
Manufacturers, health care providers, beneficiaries,
HCFA contractors and others may request that HCFA
issue a national coverage decision for a technology.
HCFA then conducts an initial review to determine
whether such a decision should be considered. At this
point in the process, HCFA can refer to the Office of
Health Technology Assessment (OHTA) within the
Agency for Health Care Policy and Research (AHCPR)
for a full assessment or inquiry. Alternatively, HCFA’s
staff can conduct a special study of its own (as was the
case with heart transplants). HCFA can issue a national
coverage decision without referring to OHTA, or it can
decline to make a national coverage decision and leave
it to the discretion of its contractors. Beneficiaries,
providers, and manufacturers have limited opportunities
to appeal HCFA’s coverage decision, but they may ask
for reconsideration, especially based on new scientific
data. HCFA’s coverage issues manual contains approximately 200 national coverage decisions. Local contractors must abide by national coverage decisions.

The Regulation of Medical Devices:
The Role of the FDA
In the United States, the FDA is responsible for
regulating medical products for safety and effectiveness,
while HCFA reviews technologies to determine whether
they will be available (that is, covered) through the
Medicare program for eligible beneficiaries. How
Medicare pays for these products is a separate issue and
depends upon the item.
While some define technology as all-encompassing
—that is drugs, devices, and biologics—the FDA regulates each of these categories differently. The FDA’s
duties regarding devices fall into two general categories:
review of a device before it reaches the market and
postmarket control after it has been cleared by the FDA.
This description is limited to the premarket process.
Both the type of premarket review and the degree of
regulation a medical device undergoes depend, in large
measure, upon the potential risk presented to patients. The
landmark Medical Device Amendments of 1976 introduced a systematic premarket regulation of medical
devices, classifying products into one of three categories:



MEDICARE COVERAGE OF
EXPERIMENTAL OR
INVESTIGATIONAL PRODUCTS
HCFA has historically interpreted “experimental”
devices or procedures to be outside the scope of the
reasonable and necessary clause. Included in the
agency’s definition of experimental is whether the



Class I—products that pose the least risk, such as
elastic bandages. Class I devices must meet certain
general controls that assure, among other things, that
the product is not adulterated or misbranded, that it
is properly labeled, that it is manufactured in a
manner that meets all specifications, and that the
FDA is notified prior to marketing.
Class II—products that pose a moderate degree of
risk, such as catheters and hypodermic needles. In
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addition to meeting Class I general controls, Class II
devices must meet any standards or other special
controls developed by the FDA for that type of device.



Class III—products that pose the most significant
potential risk, such as replacement heart valves and
extended-wear contact lenses. In addition to the
Class I and II controls, these devices must undergo
detailed and often lengthy premarket evaluation to
determine if they are safe and effective.

The product approval process. With the exception of
some custom devices and certain Class I devices, the FDA
conducts a premarket review of all medical devices before
they can be introduced into the market. This is done either
through a detailed premarket review of the device (known
as a premarket approval, or PMA) or through a more
routine premarket notification, or 510(k).





Premarket notification—A company intending to
market a product that is “substantially equivalent” to
an earlier, legally marketed device, can submit a
premarket notification application, often referred to as
a 510(k) application, to the FDA. The idea behind
premarket notification is to expedite incremental
adjustments in health care technologies through the
regulatory process. 510(k)s are typically used for
Class I and II devices, and, in some cases, for Class III
devices for which the FDA has not required a more
detailed PMA submission. With a 510(k), the company must show that the device has the same technological characteristics and the same intended use as the
earlier device already in the market. If the device
represents different characteristics, the company must
show that it is just as safe and effective as the earlier
device. Once the company receives clearance from the
FDA, it can market the product.
Premarket approval—The FDA conducts a rigorous
premarket review for those devices that represent a
potentially great risk. These include Class III products, such as implantable devices or those representing potentially significant risk of injury or illness.
Class III products also include all products that are
not substantially equivalent to an earlier device
—that is, they represent a new kind of technology
whose risk and reliability are unknown. In this case,
the FDA requires a premarket approval, or PMA,
application, which involves a wide range of physical, scientific, biological, and engineering testing
and information. In order for a company to collect
these data on patients, it must obtain approval of an
institutional review board.

In addition, a company must also submit a plan to
the FDA explaining, among other things, how it will
conduct the testing, what types of patients it will
use, what results it expects, and what risks and
precautions it believes are involved. If the FDA
considers the request to be sound, it will grant an
investigational device exemption or IDE. The IDE
allows for the device to be used in patients for the
purpose of gathering data. (An approved IDE is also
required for clinical testing of devices that undergo
marketing clearance through 510[k]).

Linking Product Safety and Efficacy to
Product Coverage and Reimbursement
Payers today have become increasingly sophisticated
and are demanding far more information beyond FDA
approval, information such as outcomes and costeffectiveness. The FDA imprimatur alone is not enough
to assure commercial success. Overwhelmingly, however, payers look to see whether, at a minimum, a
product has received FDA approval or clearance (that
is, PMA or 510[k]).
This “FDA stamp of approval” is typically the first
criterion applied, because, without it, a product may be
considered experimental or investigational. However,
these products, under limited conditions, may be
considered for coverage. “Deciding when an innovative
new therapy has moved from experimental to standard
treatment is an issue with which insurers, providers, and
public policymakers all struggle.”2
Generally, Medicare carriers will not cover experimental or investigational technologies, although much
has happened over the past few years, including the
recent growing attention to the relationship between a
technology’s FDA review status and Medicare coverage
determination. Most important was the publication of
HCFA’s “Medicare Program; Criteria and Procedures
for Extending Coverage to Certain Devices and Related
Services” final rule in the September 19, 1995, Federal
Register. The rule specifically “sets forth the process by
which the FDA will assist HCFA in identifying nonexperimental investigational devices that are potentially
covered under Medicare.”
Medicare coverage of IDEs. The September 19, 1995,
rule established in regulations that certain devices
involved in trials approved by the FDA under an IDE as
well as certain services related to those devices may be
covered under Medicare. Specifically, the rule outlines
the process by which the FDA will assist HCFA in
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identifying non-experimental investigational devices
that are potentially covered under Medicare.

example, other manufacturers have obtained FDA
approval for that device type.

Historically, the term experimental has been used
synonymously with the term investigational. Therefore, a
device categorized by the FDA as being investigational
served as an indication that it was not reasonable and
necessary within the meaning of the Medicare program.
The following is noted in the final rule:

HCFA will now consider covering Category B devices
and related services (also spelled out in the rule). Even
if an IDE device receives a Category B determination
from the FDA, Medicare coverage is not guaranteed or
mandated. Rather, HCFA will not automatically exclude the device from Medicare coverage consideration.

There is increasing recognition, however, that there
are devices that are refinements of existing technologies or replications of existing technologies by other
manufacturers. The FDA places many of these devices
within the IDE category as a means of gathering the
scientific information necessary to establish the safety
and effectiveness of the particular device, even though
there is scientific evidence that similar devices can be
safe and effective. Arguably, these devices could be
viewed as reasonable and necessary under Medicare
and recognized for payment if it were possible to
identify them in the FDA’s process.

The fundamental policy issue addressed by this rule is
the need for a mechanism to prevent HCFA from
automatically excluding from Medicare coverage all
devices that the FDA considers investigational.
IDE categorization. To that end, the rule set out a new
categorization system. To assist HCFA in its coverage
decision process, the FDA follows a categorization
process that differentiates between the clinical assessment of novel, first-of-a-kind devices and newer generations of legally marketed devices. The policy changes
in this rule reflect the categorization of investigational
devices that are the subject of FDA-approved IDEs.
Under the new categorization process, the FDA
assigns each device with an FDA-approved IDE to one
of two categories: experimental/investigational (Category A) devices, or non-experimental/investigational
(Category B) devices. A Category A device is “an
innovative device in Class III for which ‘absolute risk’
of the device type has not been established (that is,
initial questions of safety and effectiveness have not
been resolved and the FDA is unsure whether the
device type can be safe and effective.)” HCFA is,
according to the rule, to exclude from Medicare coverage a Category A device.
A Category B device is a
device believed to be in Class I or II, or a device
believed to be in Class III for which the incremental
risk is the primary risk in question (that is, underlying
questions of safety and effectiveness of that device
type have been resolved), or it is known that the
device type can be safe and effective because, for

Alternative Options for
Crossover Technologies
In a Summer 1994 Health Affairs Perspectives piece,
“How Can Medicare Keep Pace with Cutting-Edge
Technology?”—in which she expressed her individual
opinion and not her agency’s—deputy director of
HCFA’s Center for Health Plans and Providers Kathleen Buto wrote that
Therapies that are evolving from experimental to
standard practice pose some of the most difficult
coverage issues for Medicare. . . . The Medicare
program could go on as it is, basing coverage decisions on technology assessments and limiting coverage of crossover3 therapies until they become part of
standard practice. But HCFA could consider changes
that will make promising therapies available earlier
and lead to better data on use and patient outcomes.
Any changes should provide more options for providers and patients and greater flexibility for the Medicare program to revise coverage policy.
Two alternatives meet these goals: (1) broader use of
limited coverage approaches (coverage of a technology or therapy that is limited by certain criteria or
conditions) and (2) a clinical research fund or setaside (similar to the Blue Cross/Blue Shield fund used
to support breast cancer clinical trials). The fund
could be used to pay for services not otherwise
covered and would allow Medicare to support studies
of potentially beneficial treatments for the elderly or
persons with disabilities.

THE FUTURE: MEDICARE COVERAGE
POLICY CHALLENGES—OPTIONS FOR
CHANGE
According to a March 1998 white paper, “Medicare
Coverage: Time for a Public Policy Dialogue,” by the
Medical Technology Leadership Forum (MTLF),
The Health Care Financing Administration has experimented with some aspects of coverage policy, primarily on an ad hoc basis using informal guidelines and
directives. The result is that there are pressing issues
of timeliness, flexibility, and accountability in the
Medicare coverage process. In addition, major public
policy issues about technology and Medicare have not
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been addressed explicitly in an open forum. It is time for
a serious reevaluation of the Medicare coverage policy.

The MTLF paper lays out four key policy issues:









What standard of evidence should be applied to
Medicare coverage decisions? What criteria or
standards should be applied? Are they appropriate
for medical devices and procedures? What methodologies are acceptable to meet the standards? Who
defines the elements of that standard, including
concepts such as “authoritative evidence,” “demonstrated evidence,” or “relative effectiveness?”
Should HCFA defer to the FDA’s finding of safety
and effectiveness? Should cost-effectiveness be
considered? If so, how should costs and effectiveness be defined? Who should pay for the costs of
developing the data?
What is the appropriate balance between national
coverage decisions and those of local carriers?
How important is uniformity for the program? Are
there some decisions that are best left to local
decision making? What role should the opinions of
medical specialty societies play in Medicare coverage decisions? What role should producers of
technology play?
Should Medicare have a responsibility to support
and encourage medical innovation? How does this
change as Medicare transforms itself from an administrator of health care into a provider of health care
through its Medicare + Choice program?
Who should participate in coverage decisions and
how can the process be improved? Should it be
more open? More flexible? More predictable?
Where should the locus of decision making reside?
What role, if any, should cost-effectiveness play?
When should a technology be assessed? By whom?
Are there adequate appeals processes in place?

Federal Advisory Commission Act, which calls for an
open, public hearing as part of the coverage determination process. As a result of the ruling in this court case
as well as a recent GAO finding, the TAC will be
restructured to address concerns about due process in
assuring openness.
While most agree that the process needs to be more
open and public, there is less agreement as to how this
should be accomplished. The four basic options available to policymakers are






Constructive informal discussions with HCFA
among all concerned parties.
Notice and comment rulemaking.
Negotiated rulemaking.
Legislation.

Forum speakers will consider the benefits and
drawbacks of each as they discuss the past, present, and
future of Medicare coverage decision making.

THE FORUM SESSION
Donald A. Young, M.D., senior vice president for
policy and clinical services at the American Association
of Health Plans (AAHP), will open with an overview of
how we got to where we are today—a history of the
issues and lessons learned and implications for the
private sector. Before joining the AAHP, Dr. Young
was the executive director of the Prospective Payment
Assessment Commission. He also served as deputy
director of the Policy Bureau at HCFA, where he was
responsible for Medicare and Medicaid eligibility,
reimbursement, and coverage policies.

Several stakeholders have spent a great deal of time
analyzing the intricacies of the Medicare coverage
process and circulating proposals around Capitol Hill
and throughout the various federal agencies, including
HCFA, OHTA, AHCPR, and the National Institutes of
Health. Most of these proposals call for greater predictability, openness, and flexibility in the process.

Jeffrey L. Kang, M.D., M.P.H., HCFA’s chief
clinical officer and director of the Office of Clinical
Standards and Quality, will discuss where HCFA is
today vis-à-vis the Medicare coverage process. He will
look at the strengths and weaknesses of the current
system as well as what changes might occur in coverage
decision making as Medicare becomes a provider of
health care through its Medicare + Choice program. Dr.
Kang’s responsibilities include developing national
coverage policies and quality standards for Medicare
providers, collecting clinical data to support agency
initiatives, overseeing quality improvement activities,
and managing Medicare’s peer review program.

At the beginning of 1998, the Indiana Medical
Device Association challenged HCFA’s Technology
Advisory Committee (TAC) as not complying with the

Michael B. McCulley, Esq., assistant general
counsel of Johnson & Johnson will explain the implications of Medicare decision making on technology

Options under Consideration
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innovation and adoption. His present assignments
include work in the areas of general corporate and U.S.
and international regulatory law, with a primary regulatory focus on matters relating to the FDA, the European
Common Market, and HCFA. Before joining Johnson
& Johnson, Mr. McCulley was senior regulatory
counsel for the American Hospital Supply Corporation.

ENDNOTES

A panel of Capitol Hill speakers will continue the
discussion. Allison Giles, J.D., professional staff
member of the House health subcommittee of the House
Ways and Means Committee, will explore concerns of
members of Congress, focusing on HCFA’s Technology Advisory Committee. For more than two years
before joining the health subcommittee, Ms. Giles
worked on health care policy issues in the personal
office of its chairman, Rep. Bill Thomas (R-Calif.).
From 1992 to 1994, she was the assistant chief counsel
for health policy in the Office of Advocacy at the U.S.
Small Business Administration.

3. As explained by Stanley Joel Reiser in his Summer 1994
Health Affairs article, “Criteria for Standard versus Experimental Therapy,” crossover technologies—which are innovations that move between experimental and standard categories—can be defined in the following manner: “Therapies are
like trains: They exist in an oscillating motion, shuttling back
and forth between standard and experimental stations, and
sometimes taking a crossover track to pause at a place in
between them.” To define this in-between place, Reiser offers
the term “crossover therapy.”

Alexander Vachon, Ph.D., chief social security
analyst with the Senate Committee on Finance, will talk
about aspects of coverage decision making included in
the recent Balanced Budget Act, with a focus on
laboratory coverage. In addition, Mr. Vachon will touch
upon how the process affects access of care for patients.
Dr. Vachon has worked on every major spending bill
that has come before the committee since he joined it in
1995, including the Balanced Budget Act of 1995.
Previously, he was a legislative aide to Sen. Bob Dole
(R-Kans.).
Wrapping up will be Peter Hasselbacher, M.D.,
Robert Wood Johnson Health Policy Fellow with the
Senate Committee on Finance. Dr. Hasselbacher, who
has served as medical director of a large multi-specialty
group practice and as medical director and vice president for medical affairs of a 135,000-member managed
care plan, will discuss implications of government
coverage determinations on managed care programs. He
will review the origins, implications, and limitations of
HCFA’s definitions of “safe and effective,” “medically
necessary and appropriate,” and “investigational.” He
will highlight some intrinsic tensions between manufacturers and payers related to coverage determinations
that will not be easy (or perhaps desirable) to resolve.

1. Much of this section was taken from the 1995 Reference
Guide for the Health Care Technology Industry, Health Care
Technology Institute, Alexandria, Virginia, 22-25.
2. Stanley Joel Reiser, “Criteria for Standard versus Experimental Therapy,” Health Affairs (Medical Innovation: Risks
and Rewards), Summer 1994, 127.
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Figure 1
Medicare Local, Regional, and National Coverage

Source: Gordon B. Schatz of Reed, Smith, Shaw & McClay, Washington, DC, 1994 (updated 1998).

